Printer Friendly

FDA approves Nexium[R] for the treatment of short-term GERD in children 1 to 11 years old.

AstraZeneca recently announced that the U.S. Food and Drug Administration (FDA) has approved the use of NEXIUM[R] (esomeprazole magnesium) in children ages 1 to 11 years old for the short-term treatment of gastroesophageal reflux disease (GERD) for up to eight weeks, helping to address an important unmet need for pediatric patients.

NEXIUM received approval in April 2006 for adolescents 12 to 17 years old for the treatment of GERD. "GERD has become increasingly common in children, and, if left untreated, can lead to potentially serious complications such as erosive esophagitis," said Mark A. Gilger, MD, Chief of Service, Gastroenterology, Hepatology and Nutrition, Texas Children's Hospital. The availability of a proven, effective treatment like NEXIUM with an established safety profile is an important step in the treatment of this chronic condition." For more information, visit
COPYRIGHT 2008 EP Global Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:gastroesophageal reflux disease; WHAT'S HAPPENING
Publication:The Exceptional Parent
Article Type:Brief article
Date:May 1, 2008
Previous Article:Cherokee Uniforms call for Comfort Awards nominations.
Next Article:Product & services.

Related Articles
Gastroesophageal reflux disease (hiatal hernia and heartburn).
Food and Drug Administration clears permanent of acid reflux device.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters